宫颈托与阴道黄体酮预防双胎妊娠短宫颈早产的比较:随机对照试验的经济学分析
在越南胡志明市美德医院开展的随机对照试验(2016年3月4日至2017年6月3日)基础上进行经济学分析,比较宫颈托与阴道黄体酮用于双胎妊娠且宫颈长度<38 mm孕妇的成本效果。共300例孕妇随机分组,宫颈托组150例、阴道黄体酮组150例。宫颈托组无病生存新生儿率显著高于黄体酮组(81.4% vs 73.5%),且每例平均总成本更低(3146 € vs 3570 €)。
要点
- 双胎妊娠短宫颈者,宫颈托组无病生存新生儿率81.4% vs 阴道黄体酮组73.5%,相对风险1.11(95%CI 1.02-1.21),P=0.02。
- 宫颈托组每例平均总成本3146 € vs 黄体酮组3570 €,绝对差-424 €(95%CI -842至-3 €),P=0.048。
- 每无病生存新生儿成本宫颈托组2492 € vs 黄体酮组2639 €,绝对差-147 €(95%CI -284至10 €),P=0.035。
核心结论
- 在双胎妊娠且短宫颈的孕妇中,与阴道黄体酮相比,宫颈托显著提高无病生存新生儿率并降低费用。
研究设计与样本
- 基于一项随机对照试验的经济学分析,在越南胡志明市美德医院开展,比较宫颈托与阴道黄体酮。
- 研究期间筛查1113例双胎妊娠孕妇,300例符合随机对照试验纳入标准并知情同意,随机分为宫颈托组(n=150)和阴道黄体酮组(n=150)。
- 宫颈托组失访2例,阴道黄体酮组失访1例。
- 效果指标为无病生存新生儿,增量成本效果比计算为宫颈托组相比黄体酮组每额外获得一例无病生存新生儿所需的增量成本。
- 进行了概率敏感性分析和单因素敏感性分析。
主要发现
- 无病生存新生儿率宫颈托组241/296(81.4%)vs 阴道黄体酮组219/298(73.5%),相对风险1.11(95%CI 1.02-1.21),P=0.02。
- 每例平均总成本宫颈托组3146 € vs 阴道黄体酮组3570 €,绝对差-424 €(95%CI -842至-3 €),P=0.048。
- 每无病生存新生儿成本宫颈托组2492 € vs 阴道黄体酮组2639 €,绝对差-147 €(95%CI -284至10 €),P=0.035。
关键数值与推荐
- 纳入标准为双胎妊娠、孕16至22周、宫颈长度<38 mm。
- 效果指标为无病生存新生儿。
- 增量成本效果比计算为宫颈托组相比黄体酮组每额外获得一例无病生存新生儿所需的增量成本。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the cost-effectiveness of cervical pessary vs vaginal progesterone to prevent preterm birth and neonatal morbidity in women with twin pregnancy and a short cervix. METHODS: Between 4 March 2016 and 3 June 2017, we performed this economic analysis following a randomized controlled trial (RCT), performed at My Duc Hospital, Ho Chi Minh City, Vietnam, that compared cervical pessary to vaginal progesterone in women with twin pregnancy and cervical length < 38 mm between 16 and 22 weeks of gestation. We used morbidity-free neonatal survival as a measure of effectiveness. Data on pregnancy outcome, maternal morbidity and neonatal complications were collected prospectively from medical files; additional information was obtained via telephone interviews with the patients. The incremental cost-effectiveness ratio was calculated as the incremental cost required to achieve one extra surviving morbidity-free neonate in the pessary group compared with in the progesterone group. Probabilistic and one-way sensitivity analyses were also performed. RESULTS: During the study period, we screened 1113 women with twin pregnancy, of whom 300 fulfilled the inclusion criteria of the RCT and gave informed consent to participate. These women were assigned randomly to receive cervical pessary (n = 150) or vaginal progesterone (n = 150), with two women and one woman, respectively, being lost to follow-up. The rate of morbidity-free neonatal survival was significantly higher in the pessary group compared with the progesterone group (n = 241/296 (81.4%) vs 219/298 (73.5%); relative risk, 1.11 (95% CI, 1.02-1.21), P = 0.02). The mean total cost per woman was 3146 € in the pessary group vs 3570 € in the progesterone group (absolute difference, -424 € (95% CI, -842 to -3 €), P = 0.048). The cost per morbidity-free neonate was significantly lower in the pessary group compared with that in the progesterone group (2492 vs 2639 €; absolute difference, -147 € (95% CI, -284 to 10 €), P = 0.035). CONCLUSION: In women with twin pregnancy and a short cervix, cervical pessary improves significantly the rate of morbidity-free neonatal survival while reducing costs, as compared with vaginal progesterone. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Le KD, Nguyen LK, Nguyen LTM, et al. Cervical pessary vs vaginal progesterone for prevention of preterm birth in women with twin pregnancy and short cervix: economic analysis following randomized controlled trial. Ultrasound Obstet Gynecol. 2020. PMID: 31432562. doi:10.1002/uog.20848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。